BioSpace News Archive

Therapeutic Solutions International, Inc. (TSOI) announced today new data and a patent filing from its Subsidiary Company Res Nova Bio which, according to Company scientists, is a potential breakthrough in the field of immunotherapy of cancer.

Liminal BioSciences Inc., is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act pursuant to which SALP, a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences not currently owned by SALP or its affiliates and associates at a price of US$8.50 per Share, payable in cash.

A Purdue researcher is taking a giant leap forward in the fight against drug-resistant strains of malaria in developing countries.

Nephron Pharmaceuticals Corporation celebrated a successful $350 million capital raise – led by BlackRock Capital Investment Advisors, LLC and PNC Bank, National Association – to support future growth of the pharmaceutical manufacturer.

United Urology Group and its Affiliate Practices and Prostate Centers USA® are pleased to announce a groundbreaking initiative in the treatment of Benign Prostatic Hyperplasia.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that on September 5, 2023, Anika granted restricted stock units covering 10,000 shares of common stock to one newly hired non-executive employee.

Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of an aggregate of 39,000 restricted stock units of Arcutis’ common stock to six newly hired employees.

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 8,750 shares of its common stock to one newly hired employee, consisting of inducement stock options to purchase an aggregate of 5,000 shares of common stock and inducement restricted stock units, covering an aggregate of 3,750 shares of its common stock.

Integrated BioPharma, Inc. reports its financial results for the quarter and fiscal year ended June 30, 2023.

GSK plc announced that the US Food and Drug Administration has approved Ojjaara for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, in adults with anemia.